SalvaRx Group PLC (SalvaRx) is a drug development company focused on acquiring and operating drug development programmes in immuno-oncology. It owns 60.49% of iOx Therapeutics Limited, a company that is developing a pipeline of anti-cancer treatments based on iNKT cells under license from the Ludwig Institute for Cancer Research. SalvaRx’s strategy focuses on the acquisition of immune-oncology therapeutics that are complementary to anti-PD1 or anti-PDL1 therapies. The Company uses a group of industry and academic experts to assess information on acquisition and investment targets. SalvaRx joined AIM on 22 March 2016 via a reverse takeover of 3Legs Resources PLC.
The number of shares in issue is 36,466,619 ordinary shares of 2.5p each. The company does not hold any share in treasury. The percentage of shares that is not in public hands is 73.35%.
Shareholders with >3%
|Name||Number of Shares||Percentage|
|Dr. Gregory Bailey||13,320,291||36.53%|